Фактор роста эндотелия сосудов (VEGF) в крови больных первичными новообразованиями костей
Диссертация
Анализ средних концентраций УЕвР как в группе контроля, так и в группе больных различными новообразованиями костей показал, что полученные нами показатели вполне согласуются с результатами последних исследований, опубликованных в литературе. Концентрации УЕвР в группе контроля варьировали от 20,65 до 461,99 пг/мл (медиана 126,48- среднее±стандартное отклонение — 150,87±113,55). В общей группе… Читать ещё >
Список литературы
- Asahara Т., Takahashi Т., Masuda H., Kalka C., Chen D. VEGF contributes to postnatal neovasculorization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO, 18: 3964−3972, 1999.
- Asano M, Yukita A, Matsumoto T et al. Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factorl21. Cancer Res 1995−55:5296−5301.
- Asano M, Yukita A, Suzuki H. Wide spectrum of antitumor activity of a neutralizing monoclonal antibody to human vascular endothelial growth factor. Jpn J Cancer Res 1999−90:93−100.
- Ayala G, Liu C, Nicosia R, Horowits S, Lackman R. Microvasculature and VEGF expression in cartilaginous tumors. Hum Pathol 2000, 3 l (3):34I-6.
- Bacci G., Picci P., Ruggieri P., Merucuri M., Avella M., Capanna R., Brach.
- Blood C.H. and Zetter B.R. Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochim Biophys Acta 1990, 1032: 89−118.
- Boehm T, Folkman J, Browder T, O’Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997- 390: 404−407.
- Carmeliet P, Ferreira V, Breier G et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996−380:435−439.
- Claesson-Welsh L, Welsh M, Ito N, et al. Angiostatin induces endothelial cell apoptosis and activation of focal adgesion kinase independently of the integrin-binding motif RGD. Proc Natl Acad Sci USA 1998- 95:5579−5583.
- Colvard D.S., Eriksen E.F., Keeting P.E., et al. Proc Natl Acad Sci USA Biochemistry. V-86:854−857- 1989.
- David Lynden. Bone marrow cells contribute to tumor blood supply and growth-1,2001.
- Deckers M, Karperien M et al. Expression of Vascular Endothelial Growth Factor and Treir Receptors during Osteoblast Differentiation. Endocrinology, 141: 1667−1674, 2000.
- Delany A.M., Dong Y., Canalis E. Mechanisms of glucocorticoid action in bone cells. Cell Biochem. 56,3:295−302- 1994.
- Dhanabal M, Volk R, Ramchandran R, et al. Endostatin induces endothelial cell apoptosis. J Biol Chem 1999- 274:11 721−11 726.
- Dvorak HF, Brown LF, Detmar M et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995−146:1029−1039.
- Ellis LM, Walker RA, Gasparini G. Is determination of angiogenic activity in human tumours clinically useful? Eur J Cancer 1998−34:609−618.
- Eriksen E.F., Colvard D.S., BergN.G. Evidence of estrogen receptors in normal human osteoblast-like cells. Science 241:84−86- 1988.
- Ferrara N, Davis-Smyth T: The biology of vascular endothelial growth factor. EndocrRev 1997, 18:4−25
- Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989−161:851−858.
- Ferrara N, Houck K, Jakeman L et al. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 1992−13:18−32.
- Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999, 77: 527−43.
- Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int 1999, 56: 794−814.
- Folkman J, Cole P, Zimmerman S. Tumor behavior in isolated perfused organs: in vitro growth and metastases of biopsy material in rabbit thyroid and canine intestinal segment. Ann Surg 1966−164:491−502.
- Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 1995−333:1757−1763.
- Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971−285:1182−1186.
- Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990, 82: 4−6.
- Gasparini G, Harris AL. Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J Clin Oncol 1995−13:765−782.
- Gerber HP, Hillan KJ, Ryan AM et al. VEGF is required for growth and survival in neonatal mice. Development 1999- 126:1149−1159.
- Gimbrone MA Jr, Cotran RS, Leapman SB et al. Tumor growth and neovascularization: an experimental model using the rabbit cornea. J Natl Cancer Inst 1974−52:413−427.
- Gimbrone MA Jr, Leapman SB, Cotran RS et al. Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 1972−136:261−276.
- Glasser D.B., Lane J.M., Huvos A.G., Marcove R.C. and Rosen G. Survival, prognosis and therapeutic respose in osteogenic sarcoma: the Memorial Hospital Experienca. Cancer (Phila.), 69: 698−708, 1992.
- Gordon M.S., Talpaz M., Margolin K. et al. Phase I trial of recombinant humanized monoclonal anti-vascular endothelial growth factor (anti-VEGF
- Mab) in patients (pts) with metastatic cancer. Proc Am Soc Clin Oncol 1998., 17:210.
- Goustin A.F., Leof E.B., Shiplay G.D., Moses H.L. Growth facors and cancer. Cancer Res. 46:1015−1046- 1986.
- Grunstein J, Roberts WG, Mathieu-Costello O et al. Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Res 1999−59:1592−1598.
- Guidi AJ, Schnitt SJ, Fischer L et al. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast. Cancer 1997−80:1945−1953.
- Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996−86:353−364.
- Hauser S, Wech HA: A heparin-binding form of placental growth factor (Plgf-2) is expressed in human umbilical vein endothelial cells, and in placenta. Growth Factors 1993, 9:259−268
- Holzer G, Obermair A, Koschat M, Preyer O, Kotz R, Trieb K. Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with malignant bone tumors. Med Pediatr Oncol 2001- 601−4.
- Horner A, Bord S, Kelsall A W, Coleman N, Comptston JF. Tie2 ligands angiopoietin-1 and angiopoietin-2 are coexpressed with vascular endothelial cell growth factor in growing human bone. Bone 2001 Jan 28:65−71
- Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N: Dual regulation of vascular endothelial growth factor availability by genetic and proteolytic mechanisms. J Biol Chem 1992, 267:26 032−26 037
- Huvos A.G., Heiweil M., Bretsky S.S. The pathology of malignant fibrous histiocytoma of bone: a study of 130 patient. Am. J. Surg. Pathol., 9:853−71- 1985.
- I Iyder SM, Murthy L, Stancel GM. Progestin regulation of vascular endothelial growth factor in human breast cancer cells. Cancer Res 1998−58:392−395.
- Joukov V, Sorsa T, Kumar V, Jeltsch M, Claesson-Welsh L, Cao Y, Saksela O, Kalkkinen N, Alitalo K: Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J 1997, 16:3898−3911
- Kato T, Kimura T, Ishii N et al. The methodology of quantitation of microvessel density and prognostic value of neovascularization associated with long-term survival in Japanese patients with breast cancer. Breast Cancer Res Treat 1999−53:19−31.
- Kawauchi S., Fukuda T. and Tsuneyoshi M. Angiogenesis does not correlate with prognosis or expression of vascular endothelial growth factor in synovial sarcoma. Oncol. Rep. 6: 959−964,1999.
- Kaya M., Wada T., Akatsuka T., Kawaguchi S., Nagoya S. et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res, 2000, 6, 572−577.
- Kieser A, Weich H, Brandner G, Marine D, Kolch W: Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 1994,9:963−969
- Kim KJ, Li B, Winer J et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993−362:841−844.
- Kost C, Benner K, Stockmann A, Linder D, Preissner KT. Limited plasmin proteolisis of vitronectin. Characterization of the adhesion protein as morpho-regulatory and angiostatin-binding factor. Eur J Biochem 1996- 236: 682−688.
- Kukk E, Lymboussaki Taira S, Kaipanen A, Jeltsch M, Joukov V, Alitalo K: VEGF-C receptor binding, and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development 1996, 122:3829−3837
- Kumar S, Ghellal A, Li C et al. Breast carcinoma: vascular density determined using CD 105 antibody correlates with tumor prognosis. Cancer Res 1999−59:856−861.
- Kushlinskii N, Babkina I, Solov’ev Y, Trapeznikov N. Vascular endothelial growth factor and angiogenin in the serum of patients with osteosarcoma and Ewing’s tumor. Bull Exp Biol Med 2000- 130: 691−3.
- Leenders W, Lubsen N, Altena M, Clauss M, Deskers M, et al. Design of a Variant of Vascular Endothelial Growth Factor-A (VEGF-A) Antagonizing KDR/Flk-1 and Flt-1. Lab Invest 82: 473−481, 2002.
- Leung DW, Cachianes G, Kuang WJ et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989−246:1306−1309.
- Lucas R, Holmgren L, Garciaa I, et al. Multiple forms of angiostatin induce apoptosis in endothelial cells. Blood 1998- 92:4730−4741.
- Luo JC, Toyoda M, Shibuya M. Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelialgrowth factor/permeability factor neutralizing antibody. Cancer Res 1998−58:2594−2600.
- Maeda T, Kawane T, Horiuchi N. Statins Augment Vascular Endothelial Growth Factor Expression in Osteoblastic Cells via Inhibition of Protein Prenylation. Endocrinology, 144: 681−692,2003.
- McLeskey SW, Kurebayashi J, Honig SF et al. Fibroblast growth factor 4 transfection of MCF-7 cells produces cell lines that are tumorigenic and metastatic in ovariectomized or tamoxi fen-treated athymic nude mice. Cancer Res 1993−53:2168−2177.
- Millauer B, Shawver LK, Plate KH et al. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 1994−367:576−579.
- Millauer B, Wizigmann-Voos S, Schnurch H et al. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993−72:835−846.
- Mohan S., Baylink D. Bone growth factors. Clin. Ortoped. And Related Res. 263:30−43- 1991.
- Moser TL, Stack MS, Asplin I, et al. Angiostatin binds ATP syntase on the surfase of human endothelial cells. Proc Natl Acad Sci USA 1999- 96:28 112 816.
- Mukhopadhyay D, Tsiokas L, Sukhatme VP. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res 1995−55:6161−6165.
- MuIler Y., Li B., Christinger H., Wells J et al. Vascular Endothelial Growth Factor: Crystal structure and functional mapping of the kinase domain receptor binding site. Biochemistry, 1997, 94, 7192−7197.
- Nagy J. A., Brown L.F., Senger D.R., Lanir N., Van De Water L., Dvorak A.M. and Dvorak H.F. Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. Biochim. Biophys. Acta., 948: 305 326, 1989.
- Nicosia R. F What is the role of vascular endothelial growth factor-related molecules in tumor angiogenesis? Am J of Pathology 1998, 153: 11−16.
- O’Reilly MS, Holmgre L, Chen CC, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Med 1996- 2:689 692.
- P?rast * C., Mroczkowski B., Pinko C. et al. Characterization and kinetic mechanism of catalytic domen of human vascular endothelial growth factor receptor-2 tyrosine kinase (VEGFR2 TK), a key enzyme in angiogenesis. Biochemistry, 1998,37,16 788−16 801.
- Poltorak Z, Cohen T, Silvan R, Kandelis Y, Spira G, Vlodavsky I, Keshet E, Neufeld G: VEGF145, a secreted vascular endothelial growth factor isoform that binds to the extracellular matrix. J Biol Chem 1992, 272:7151−7158
- Praus M., Wauterickx K., Collen D., Gerard R.D. Reduction of tumor cell migration and metastasis by adenoviral gene transfer of plasminogen activator inhibitors. Gene Ther. Fb-6(2):227−36, 1999.
- Presta LG, Chen H, O’Connor SJ et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997−57:4593−4599.
- Ramchandran R, Dhanabal M, Volk R, et al. Antiangiogenic activity of restin, NC10 domain of human collagen XV: comparison to endostatin. Biochem Biophys Res Commun 1999- 255: 735−739.
- Rastinejad F, Polverini PJ, Bouck NP. Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell 1989−56:345−355.
- Risau W. Mechanisms of angiogenesis. Nature 1997−386:671−674.
- Ristimaki A, Narko K, Enholm B, Joukov V, Alitalo K: Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor C. J. Biol Chem 1998, 273:8413−8418
- Salven P, Lymboussaki A, Heikkila, Jaaskela-Saari, Aase K, von Euler G, Eriksson U, Alitalo K, Joensuu H: Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. Am J Pathol 1998, 153:103−108
- Senger DR, Van de Water L, Brown LF et al. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 1993−12:303−324.
- Shalaby F, Ho J, Stanford WL et al. A requirement for Flkl in primitive and definitive hematopoiesis and vasculogenesis. Cell 1997−89:981−990.
- Sowter HM, Corps AN, Evans AL, Clark DE, Charnock-Jones DS, Smith SK: Expression and localization of the vascular endothelial growth factor family in ovarian epithelial tumors. Lab Invest 1997, 77:607−614
- Steinbach N., Process of tumor growth- Science report-2., 2001.
- Tanaka Y., Ijiri R., Kato K., Nishi T., Nishihira H., Aida N. Intrapulmonary lymph nodes in children versus lung metastases. Med. Pediatr. Oncol., Dec., 33(6): 580−2, 1999.
- Terman BI, Carrion ME, Kovacs E et al. Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene 1991−6:1677−1683.
- Tsurumi Y, Murohara T, Krasinski K et al. Reciprocal relation between VEGF and NO in the regulation of endothelial integrity. Nat Med 1997−3:879−886.
- Weidner N, Folkman J, Pozza F et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992−84:1875−1887.
- Weidner N, Semple JP, Welch WR et al. Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma. N Engl J Med 1991−324:1−8.
- Weinstat-Saslow DL, Zabrenetzky VS, VanHoutte K et al. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res 1994−54:6504−6511.
- Yamada Y, Nezu J, Shimane M, Ilirata Y: Molecular cloning of a novel vascular endothelial growth factor, VEGF-D. Genomics 1997,42:483−488
- Yihai Cao, Hua Chen, Li Zhou, Ming-Ko Chiang, Bela Anand-Apte, James A. Weatherbee, Yongda Wang, Faye Fang, John G. Flanagan, Monica Lik-Shing Tsang. Heterodimers of Placenta Growth Factor/Vascular Endothelial Growth Factor. JBC, 1996, 271: 3154−3162
- Zajchowski DA, Band V, Trask DK et al. Suppression of tumor-forming ability and related traits in MCF-7 human breast cancer cells by fusion with immortal mammary epithelial cells. Proc Natl Acad Sei USA 1990−87:2314−2318.
- Zelzer E, McLean W, Yin-Shan Ng, Fukai N, Reginato AM, Lovejoy S et al. Skeletal defects in VEGF 120/120 mice reveal multiple roles for VEGF in skeletogenesis. Development, 129: 1893−1904, 2002.
- Zhang HT, Craft P, Scott PA et al. Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. J Natl Cancer Inst 1995−87:213−219.
- Zhang L, Kharbanda S, Chen D et al. MCF-7 breast carcinoma cells overexpressing FGF-1 form vascularized, metastatic tumors in ovariectomized or tamoxifen-treated nude mice. Oncogene 1997−15:2093−2108.
- Zheng MH, Xu J, Robbins P, Pavlos N, Wysocky S, Kumta SM, Wood DJ, Papadimitriou JM. Gene Expression of Vascular Endothelial Growth Factor in giant cell tumors of bone. Hum Pathol 2000, 31 (7):804−12.
- Ziehe M, Maglione D, Ribatti D, Morbidelli L, Lago CT, Battisti M, Paoletti I, Barra A, Tucci M, Parise G, Vincenti V, Granger Ш, Viglietto G, Persico MG: Placenta growth factor-1 is chemotactic, mitogenic and angiogenic. Lab Invest 1997, 76:517−531
- Аббасов Ф.А. Метастазы злокачественных опухолей костей. Диссертация РОНЦ РАМН. Москва — 2000.
- Амирасланов А.Т. Комплексные методы лечения больных остеогенной . саркомой// Дисс.Док.мед.наук.- М, — 1984.
- Бабкина И.В. Ингибиторы апоптоза вкрови больных новообразованиями костей// Дисс. д.м.н.- М.- 2000.
- Виноградова Т.П. Опухоли костей. М., Медицина.- 1973.
- Карамышева А.Ф. Ангиогенез опухоли: механизмы, новые подходы ктерапии. Канцерогенез под ред.Д. Г. Заридзе.-М. Научный мир. 2000.С.298 309.
- Костылева О.И., Герштейн Е. С., Радченко A.A. и др. Клиническое значение рецепторов эпидермального фактора роста и их лигандов при остеогенной саркоме// Вопр.биол.мед. и фарм.хим.-1998.- № 1.- с.30−34.
- Некачалов B.B. Патология костей и суставов. Руководство.- СПб.: Сотис, 2000.-288с.
- Патолого-анатомическая диагностика опухолей человека: Руководство в 2 томах.Т.2/Под ред. Н. А. Краевского, А. В. Смолянникова, Д. С. Саркисова. -4-е изд., перераб. и доп. М.:Медицина. --1993.-688с.
- Синюков П.А. Современные подходы к химиотерапии остеогенной саркомы// Дисс.Докт.Мед.Наук. Москва.- 1993.
- Соловьев Ю.Н. Опухоли и опухолеподобные поражения скелета. (Опыт изучения 4899 наблюдений)// Вестник ОНЦ РАМН. 1998.-№ 1.-С. 13−18.
- Трапезников Н. Н, Алиев М. Д., Синюков П. А., Щербаков С. Д., Соколовский В. А., Тепляков В. В., Мачак Г. Н. Прогресс и перспективы развития методов лечения злокачественных опухолей костей. Вестник РОНЦ-1:7−13- 1998.
- Трапезников H.H., Л.А.Еремина, А. Т. Амирасланов, П. А. Синюков. Опухоли костей. М. Медицина -1986.
- Трапезников H.H., Соловьев Ю. Н., Еремина JI.A., Амирасланов А. Т. Саркомы костей:(Клиника, диагностика, лечение).- Ташкент, Медицина.-1983.-314 с.
- Трапезников H.H., Соловьев Ю. Н., Еремина JI.A., Амирасланов А. Т., Феденко А. Н., Синюков П. А., Григорова Т. М., Токарева З. И., Ковалевский Е. Е., Готько Е. С. Прогресс в лечении остеогенной саркомы. Вестник ОНЦ РАМН России, № 1, С:3−9- 1993.
- Юсифов А.И. Активаторы плазминогена урокиназного и тканевого типов и их ингибитор при опухолях костей//Дисс. К.б.н.- М.-2001.